| | |

Tag search: "Johnson "

Non communicable diseases

U.S. Supreme Court ruling threatens massive talc litigation against J&J

Johnson & Johnson is seizing upon a U.S. Supreme Court ruling limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer. A fifth of the plaintiffs have cases pending in state court in St. Louis, where juries in four trials have hit J&J and a talc supplier with $307 million in verdicts. Those four cases and most of the others on the St. Louis docket involve out-of-state plaintiffs suing an out-of-state company. On Monday, the Supreme Court ruled 8-1 in a case involving Bristol-Myers Squibb Co that state courts cannot hear claims against companies that are not based in the state when the alleged injuries did not occur there

June 20, 2017

Opioid Costs Push Struggling States to Dust Off Tobacco Strategy

State and local leaders fighting a worsening opioid-abuse epidemic are studying tactics used in the tobacco lawsuits of the 1990s, as they try to claw back billions from the companies who make and sell the powerful painkillers. More than 20 U.S. states, counties and cities have sued firms including Johnson & Johnson, Purdue Pharma Inc., and McKesson Corp. in the past year, claiming they fueled a public-health crisis with misleading marketing and aggressive distribution of opioids. Attorneys general in Alaska and Tennessee are also considering lawsuits as their health and legal budgets are stretched to a breaking point by the surge in addictions, overdoses and crime

June 14, 2017

Will AstraZeneca's SGLT2-favoring data win the class a shot at front-line diabetes use?

A real-world analysis showed that SGLT2 diabetes meds from AstraZeneca, Johnson & Johnson and the Eli Lilly-Boehringer Ingelheim team could dramatically cut down on heart failure hospitalizations and deaths. Now, new analyses have confirmed those findings—and may make a case for using the class earlier in treatment, AZ’s execs suggest. Researchers separated patients into two groups, one with existing CV disease and the other without. They saw “the same signal, just as robust, in those two different patient populations in terms of the SGLT2 class lowering the risk of hospitalizations for heart failure and death as well,” Jim McDermott, AstraZeneca’s Medical Affairs lead for diabetes, said

June 13, 2017
Fierce Pharma, PR Newswire

J&J diabetes drug shows heart benefit in large safety study

Johnson & Johnson`s type 2 diabetes drug Invokana significantly reduced the risk of serious heart problems in patients with established heart disease or at elevated risk in a pair of large studies, according to data presented at a medical meeting. The medicine also led to a reduced risk of hospitalization for heart failure and protection against kidney function decline. But the risk of amputations, particularly of toes or feet, was double versus placebo in the studies of 10,142 patients with type 2 diabetes

June 12, 2017
June 13, 2017
Pharmacy Practice News, Tech Times

Health systems

Missouri attorney general sues opioid manufacturers

ssouri has become the third U.S. state to accuse major drug manufacturers of fraudulently misrepresenting the risks of opioid painkillers now at the centre of a national addiction epidemic. Missouri Attorney General Josh Hawley said his office filed a lawsuit in a state court against Purdue Pharma LP, Johnson & Johnson`s Janssen Pharmaceuticals and a unit of Endo International Plc. Last week a bipartisan group of state attorneys general announced an investigation. Purdue, J&J and Endo were previously sued in similar lawsuits by the Ohio and Mississippi attorneys general, who also targeted Teva Pharmaceutical Industries Ltd and Allergan Plc

June 21, 2017

Communicable diseases

Johnson & Johnson's flu drug succeeds in mid-stage trial

J&J said trial data showed that treatment with pimodivir alone resulted in a statistically significant reduction in viral load in patients over seven days from the start of dosing, when compared with a placebo. Adding pimodivir to oseltamivir also resulted in a significantly lower viral load compared to those who received pimodivir alone, the company added. Pimodivir was granted the U.S. Food and Drug Administration`s "fast-track" status in March due to its potential to address medication for patients who develop the influenza A infection and are hospitalized, or are at high risk of related complications

June 14, 2017